Myocilin
| Catalog# | Product Description | Host Species | Nature | Cross reactivity | Quantity | Volume | Price |
|---|---|---|---|---|---|---|---|
| Myo-101AP | Myocilin N-terminal antibodies | Rabbit | AP | r, m, h, monk | 100.0 ug | 150-500 ul |
$245.00
|
| Myo-112AP | Myocilin mid-region antibodies | Rabbit | AP | r, m, h, monk | 100.0 ug | 150-500 ul |
$245.00
|
| Myo-121AP | Myocilin C-terminal antibodies | Rabbit | AP | r, m, h, monk | 100.0 ug | 150-500 ul |
$245.00
|
| FITC-Myo100 | FITC-conjugated N-terminal antibodies | Rabbit | FITC-AP | r, m, h, monk | 100.0 ug | 150-500 ul |
$350.00
|
| FITC-Myo110 | FITC-conjugated mid-region antibodies | Rabbit | FITC-AP | r, m, h, monk | 100.0 ug | 150-500 ul |
$350.00
|
| FITC-Myo120 | FITC-conjugated C-terminal antibodies | Rabbit | FITC-AP | r, m, h, monk | 100.0 ug | 150-500 ul |
$350.00
|
| P-Myo100 | N-terminal antigenic blocking peptide | n/a | Synthetic peptide | n/a | 250.0 ug | 100 ul |
$125.00
|
| P-Myo110 | Mid-region antigenic blocking peptide | n/a | Synthetic peptide | n/a | 250.0 ug | 100 ul |
$125.00
|
| P-Myo120 | C-terminal antigenic blocking peptide | n/a | Synthetic peptide | n/a | 250.0 ug | 100 ul |
$125.00
|
| PC-Myo | WB positive control for Myo | n/a | Protein in ready-to-use buffer | n/a | 0.0 ug | 150 ul |
$185.00
|
|
A
|
pproximately 4 years ago, the first major (biochemical, molecular biologic, and biologic) insight into primary open-angle glaucoma (POAG) was the presence of mutations in the myocilin (Trabecular meshwork-induced Glucocorticoid Response (Myo/TIGR) gene were related to certain forms of juvenile onset of this disease. Since then, a great deal of work has been done to determine the possible mechanisms by which MYOC/TIGR might cause not only juvenile but also adult-onset primary open-angle glaucoma. Mutation in the myocilin gene is associated with 4% (familial form) of glaucoma cases. Glaucoma is a heterogeneous eye disease and a major cause of blindness worldwide. It has been shown that primary open angle glaucoma (POAG)-associated mutations have been found in the trabecular meshwork inducible glucocorticoid response gene (TIGR), also known as the myocilin gene (MYOC), at the GLC1A locus on chromosome 1q21-q31 (1). Mutation in the TIGR protein coding region is mutated in POAG patients range from 3-4%. Myocilin is found as myocilin-Myocilin complex in the human aqueous humor and these interactions occur between amino acid 117-166 lying with in the leucine zipper motifs. Site directed mutations of the amino acid leucine in the leucine zipper results in disruption of these interactions and mutation (2).
The human clone encoding for Myocilin protein of molecular weight of 55 kDa has been isolated and characterized (4). Myocilin, which resembles Myosin, is expressed preferentially in the ciliary rootlets and the basal body of the connecting cilium of the photoreceptor cells. The deduced amino acid sequence of the human myocilin showed significant homologies with non-muscle myosin of dictyostilium discoideum in the N-terminal region and also with olfactomedin of bullfrog in the C-terminal region. Myocilin has a leucine zipper like motif that interacts with other cytoskeletal proteins.
The TIGR/myocilin protein is a 55 kDa protein expressed in RPEs. The myocilin antibodies were generated against three epitopes two from close to the N-terminus of the protein and one from the C-terminal end. Anti-Myocilin antibodies were generated against KLH conjugated peptides that are unique to human myocilin protein. The polyclonal antibody strongly labels a 55kDa protein in RPE cell extracts. Anti-Myocilin-selective antibodies are also available in affinity-purified form for confocal, Western blotting and immunocytochemical analyses. FabGennix Inc. will also conjugate antibodies with fluorescent probes upon request at extra charge. FabGennix Inc. also provides antibodies against proteins that are involved in retinal degenerative diseases such as various Anti-PDE antibodies, Anti-EFEMP1, Anti-Orphan receptor G-75; Anti-Bestrophin, Anti-ELVOL4 and a Usher syndrome specific Anti-USH2a antibody. FabGennix Inc employs cyclic peptide methodology for generating antibodies, which results in higher titer and specificity (6).
FabGennix, Inc., will also provide Western blot positive controls for most of these antibodies in ready-to-use buffer for easy identification of respective proteins. Limited quantities of antigens are also available. Please enquire for their availability before ordering.
For research use only, not for diagnostic or therapeutic use.
Data Sheets
MSDS
General Information
Citations
Search FabGennix Product Citation Data Base
Search